What is RPL3L?
RPL3L (ribosomal protein L3-like) is a human gene on chromosome 16p13.3 that spans 10 exons (transcript NM_005061) and encodes a 407–amino acid protein of the universally conserved uL3 ribosomal protein family (UniProt Q92901). It is one of the rare "non-canonical" ribosomal protein genes: a paralog of a core ribosomal protein with a highly specialized tissue distribution.
The heart has its own ribosome
Ribosomes are the molecular machines that translate mRNA into protein. The core protein RPL3 is found in the large (60S) ribosomal subunit of essentially every cell in the body. In striated muscle — cardiac muscle and skeletal muscle — RPL3 is replaced by its paralog RPL3L, producing a muscle-specific ribosome.
Why muscle needs its own ribosome is an open question, but the biology is clear: RPL3L-containing ribosomes regulate muscle function, RPL3L expression is dynamically responsive to external stimuli, and the protein plays an essential role in myoblast growth and fusion. UniProt annotates RPL3L as an inhibitor of myotube growth and muscle function, consistent with a regulatory rather than purely structural role.
A useful analogy
Think of every ribosome as the same factory model, but the muscle version ships with a different engine — RPL3L instead of RPL3. When that engine is defective, the factory doesn't just slow down; in some cases it actively blocks the backup engine (RPL3) from compensating. That double failure is what makes CMD2D so severe (see the disease mechanism).
Gene & protein at a glance
| Feature | Detail |
|---|---|
| Gene symbol | RPL3L (ribosomal protein L3-like) |
| OMIM | 617416 (gene); 619371 (CMD2D disease entry) |
| Locus | Chromosome 16p13.3; 10 exons |
| Reference transcript | NM_005061 |
| Protein | 60S ribosomal protein L3-like, 407 aa, uL3 family (UniProt Q92901) |
| Expression | Highly specific to cardiac and skeletal muscle (striated muscle) |
| Cellular role | Core component of the 60S large ribosomal subunit in striated muscle, replacing RPL3; regulates translation in muscle; role in myoblast growth and fusion |
| Paralog | RPL3 — ubiquitously expressed; can compensate for RPL3L loss in model systems |
| Disease link | Biallelic variants → CMD2D (neonatal dilated cardiomyopathy); common variants associated with atrial fibrillation risk |
A brief scientific history
Gene & ribosome biology Disease (CMD2D)
- 1996 — Van Raay et al. clone RPL3L (GenBank U65581) from a human heart cDNA library during mapping of the autosomal dominant polycystic kidney disease region at 16p13.3. The 407-aa protein shares 77% identity with RPL3, and Northern blots show transcripts almost exclusively in heart and skeletal muscle (Genomics 37:172–176).
- 2016 — RPL3L is shown to be a functional specialist: expression in myoblasts impairs myotube growth (−23% diameter) and fusion, providing the first evidence of ribosome specialization in skeletal muscle.
- 2018 — Population sequencing associates RPL3L coding variants (p.Ala75Val; c.1167+1G>A) with atrial fibrillation risk (Thorolfsdottir et al., Communications Biology).
- 2020 — Ganapathi et al. identify biallelic missense RPL3L variants in five children with severe neonatal dilated cardiomyopathy — the first cytoplasmic ribosomal protein implicated in a non-syndromic cardiomyopathy. OMIM assigns CMD2D (619371); Al-Hassnan et al. report a homozygous p.Arg116His case.
- 2022 — Further case reports confirm autosomal recessive inheritance; an infant with fulminant DCM is successfully bridged to heart transplantation with a Berlin Heart LVAD (Das et al.).
- 2023 — Ribosome biology comes of age: Rpl3l-knockout mice are viable, with RPL3 upregulation compensating (Milenkovic et al., NAR), and RPL3L-containing ribosomes are shown to determine translation elongation dynamics required for cardiac function (Shiraishi et al., Nature Communications).
- 2023 — The first Chinese case adds a novel frameshift allele and extends the phenotype to arrhythmias and AV block (Yang et al.).
- 2026 — Murphy et al. integrate human genetics, patient tissues, and isogenic cell models into a dual loss-of-function / gain-of-function mechanism for hotspot variants; further cases reported (Zhang et al.; Mai et al.).
Open questions
RPL3L biology is young. Key unanswered questions the initiative aims to help answer:
- What mRNAs, exactly, are preferentially translated by RPL3L- versus RPL3-containing ribosomes in the neonatal heart?
- Why do Rpl3l knockout mice remain largely healthy while human biallelic variants are catastrophic — is compensation by RPL3 sufficient in mice but not in humans, or are some human variants toxic beyond simple loss of function?
- Can the RPL3 compensation pathway be pharmacologically activated as a therapy for CMD2D?
- How do hypomorphic RPL3L alleles contribute to adult-onset arrhythmia such as atrial fibrillation?